Peroxisome proliferator-activated receptor-γ in vascular biology

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 7, Issue 2, 2007, Pages 109-117

  Li, Jingjue ^a   Wang, Nanping ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

Cardiovascular risk; Diabetes; Metabolic syndrome; Peroxisome proliferator activated receptor; Thiazolidinediones

Indexed keywords

15 PROSTAGLANDIN J2; 2 [1 CARBOXY 2 [4 [2 (5 METHYL 2 PHENYL 4 OXAZOLYL)ETHOXY]PHENYL]ETHYLAMINO]BENZOIC ACID METHYL ESTER; GLITAZONE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; TROGLITAZONE; UNCLASSIFIED DRUG;

ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC HYPERTENSION; ENDOTHELIAL DYSFUNCTION; EVIDENCE BASED MEDICINE; FLUID RETENTION; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INSULIN RESISTANCE; MACROPHAGE FUNCTION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR OCCUPANCY; RESTENOSIS; REVIEW; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; SMOOTH MUSCLE FIBER; WEIGHT GAIN;

EID: 34347375795     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152907780830932     Document Type: Review

References (105)

1. Braissant, O.; Foufelle, F.; Scotto, C.; Dauca, M.; Wahli, W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology, 1996, 137, 354-366.
2. Bishop-Bailey, D. Peroxisome proliferator-activated receptors in the cardiovascular system. Br. J. Pharmacol., 2000, 129, 823-834.
3. Lakka, H.M.; Laaksonen, D.E.; Lakka, T.A.; Niskanen, L.K.; Kumpusalo, E.; Tuomilehto, J.; Salonen, J.T. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA, 2002, 288, 2709-2716.
4. Ruderman, N.; Chisholm, D.; Pi-Sunyer, X.; Schneider, S. The metabolically obese, normal-weight individual revisited. Diabetes, 1998, 47, 699-713.
5. Marx, N.; Bourcier, T.; Sukhova, G.K.; Libby, P.; Plutzky, J. PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arterioscler. Thromb. Vasc. Biol., 1999, 19, 546-551.
6. Delerive, P.; Martin-Nizard, F.; Chinetti, G.; Trottein, F.; Fruchart, J.C.; Najib, J.; Duriez, P.; Staels, B. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ. Res., 1999, 85, 394-402.
7. Falk, E.; Shah, P.K.; Fuster, V. Coronary plaque disruption. Circulation, 1995, 92, 657-671.
8. Berliner, J.A.; Navab, M.; Fogelman, A.M.; Frank, J.S.; Demer, L.L.; Edwards, P.A.; Watson, A.D.; Lusis, A.J. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation, 1995, 91, 2488-2496.
9. Pasceri, V.; Wu, H.D.; Willerson, J.T.; Yeh, E.T. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation, 2000, 101, 235-238.
10. Jackson, S.M.; Parhami, F.; Xi, X.P.; Berliner, J.A.; Hsueh, W.A.; Law, R.E.; Demer, L.L. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler. Thromb. Vasc. Biol., 1999, 19, 2094-2104.
11. Sasaki, M.; Jordan, P.; Welbourne, T.; Minagar, A.; Joh, T.; Itoh, M.; Elrod, J.W.; Alexander, J.S. Troglitazone, a PPAR-gamma activator prevents endothelial cell adhesion molecule expression and lymphocyte adhesion mediated by TNF-alpha. BMC. Physiol., 2005, 5, 3.
12. Imamoto, E.; Yoshida, N.; Uchiyama, K.; Kuroda, M.; Kokura, S.; Ichikawa, H.; Naito, Y.; Tanigawa, T.; Yoshikawa, T. Inhibitory effect of pioglitazone on expression of adhesion molecules on neutrophils and endothelial cells. Biofactors, 2004, 20, 37-47.
13. Diep, Q.N.; El Mabrouk, M.; Cohn, J.S.; Endemann, D.; Amiri, F.; Virdis, A.; Neves, M.F.; Schiffrin, E.L. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated recept-orgamma. Circulation, 2002, 105, 2296-2302.
14. Marx, N.; Mach, F.; Sauty, A.; Leung, J.H.; Sarafi, M.N.; Ransohoff, R.M.; Libby, P.; Plutzky, J.; Luster, A.D. Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J. Immunol., 2000, 164, 6503-6508.
15. Plutzky J. Peroxisome proliferator-activated receptors in endothelial cell biology. Curr. Opin. Lipidol., 2001, 12, 511-518.
16. Delerive P.; Martin-Nizard, F.; Chinetti, G.; Trottein, F.; Fruchart, J.C.; Najib, J.; Duriez, P.; Staels, B. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ. Res., 1999, 85, 394-402.
17. Satoh, H.; Tsukamoto, K.; Hashimoto, Y.; Hashimoto, N.; Togo, M.; Hara, M.; Maekawa, H.; Isoo, N.; Kimura, S.; Watanabe, T. Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPARgamma on vascular endothelial function. Biochem. Biophys Res. Commun., 1999, 254, 757-763.
18. Wang, N.; Verna, L.; Chen, N.G.; Chen, J.; Li, H.; Forman, B.M.; Stemerman, M.B. Constitutive activation of peroxisome proliferator-activated receptor-gamma suppresses pro-inflammatory adhesion molecules in human vascular endothelial cells. J. Biol. Chem., 2002, 277, 34176-34181.
19. Straus, D.S.; Pascual, G.; Li, M.; Welch, J.S.; Ricote, M.; Hsiang, C.H.; Sengchanthalangsy, L.L.; Ghosh, G.; Glass, C.K. 15-deoxydelta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc. Natl. Acad. Sci. USA, 2000, 97, 4844-4849.
20. Migita, H.; Morser, J. 15-deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) signals through retinoic acid receptor-related orphan receptor-alpha but not peroxisome proliferator-activated receptor-gamma in human vascular endothelial cells: the effect of 15d-PGJ2 on tumor necrosis factor-alpha-induced gene expression. Arterioscler. Thromb. Vasc. Biol., 2005, 25, 710-716.
21. Dubey, R.K.; Zhang, H.Y.; Reddy, S.R.; Boegehold, M.A.; Kotchen, T.A. Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats. Am. J. Physiol., 1993, 265, 726-732.
22. Law, R.E.; Meehan, W.P.; Xi, X.P.; Graf, K.; Wuthrich, D.A.; Coats, W.; Faxon, D.; Hsueh, W.A. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J. Clin. Invest., 1996, 98, 1897-1905.
23. Staels, B.; Koenig, W.; Habib, A.; Merval, R.; Lebret, M.; Torra, I.P.; Delerive, P.; Fadel, A.; Chinetti, G.; Fruchart, J.C.; Najib, J.; Maclouf, J.; Tedgui, A. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature, 1998, 393, 790-793.
24. Marx, N.; Schonbeck, U.; Lazar, M.A.; Libby, P.; Plutzky, J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ. Res., 1998, 83, 1097-1103.
25. Law, R.E.; Goetze, S.; Xi, X.P.; Jackson, S.; Kawano, Y.; Demer, L.; Fishbein, M.C.; Meehan, W.P.; Hsueh, W.A. Expression and function of PPARgamma in rat and human vascular smooth muscle cells. Circulation, 2000, 101, 1311-1318.
26. Gouni-Berthold, I.; Berthold, H.K.; Weber, A.A.; Seul, C.; Vetter, H.; Sachinidis, A. Troglitazone and rosiglitazone inhibit the low density lipoprotein-induced vascular smooth muscle cell growth. Exp. Clin. Endocrinol. Diabetes, 2001, 109, 203-209.
27. Bruemmer, D.; Yin, F.; Liu, J.; Berger, J.P.; Kiyono, T.; Chen, J.; Fleck, E.; Van Herle, A.J.; Forman, B.M.; Law, R.E. Peroxisome proliferator-activated receptor gamma inhibits expression of minichromosome maintenance proteins in vascular smooth muscle cells. Mol. Endocrinol., 2003, 17, 1005-1018.
28. Sugawara, A.; Uruno, A.; Kudo, M.; Ikeda, Y.; Sato, K.; Taniyama, Y.; Ito, S.; Takeuchi, K. Transcription suppression of thromboxane receptor gene by peroxisome proliferator-activated receptor-gamma via an interaction with Sp1 in vascular smooth muscle cells. J. Biol. Chem., 2002, 277, 9676-9683.
29. Bruemmer, D.; Yin, F.; Liu, J.; Berger, J.P.; Sakai, T.; Blaschke, F.; Fleck, E.; Van Herle, A.J.; Forman, B.M.; Law, R.E. Regulation of the growth arrest and DNA damage-inducible gene 45 (GADD45) by peroxisome proliferator-activated receptor gamma in vascular smooth muscle cells. Circ. Res., 2003, 93, e38-e47.
30. Wakino, S.; Kintscher, U.; Kim, S.; Yin, F.; Hsueh, W.A.; Law, R.E. Peroxisome proliferator-activated receptor gamma ligands inhibit retinoblastoma phosphorylation and G1--> S transition in vascular smooth muscle cells. J. Biol. Chem., 2000, 275, 22435-22441.
31. Wakino, S.; Kintscher, U.; Liu, Z.; Kim, S.; Yin, F.; Ohba, M.; Kuroki, T.; Schonthal, A.H.; Hsueh, W.A.; Law, R.E. Peroxisome proliferator-activated receptor gamma ligands inhibit mitogenic induction of p21(Cip1) by modulating the protein kinase Cdelta pathway in vascular smooth muscle cells. J. Biol. Chem., 2001, 276, 47650-47657.
32. Bruemmer, D.; Berger, J.P.; Liu, J.; Kintscher, U.; Wakino, S.; Fleck, E.; Moller, D.E.; Law, R.E. A non-thiazolidinedione partial peroxisome proliferator-activated receptor gamma ligand inhibits vascular smooth muscle cell growth. Eur. J. Pharmacol., 2003, 466, 225-234.
33. de Dios, S.T.; Bruemmer, D.; Dilley, R.J.; Ivey, M.E.; Jennings, G.L.; Law, R.E.; Little, P.J. Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-gamma ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation. Circulation, 2003, 107, 2548-2550.
34. Babaev, V.R.; Yancey, P.G.; Ryzhov, S.V.; Kon, V.; Breyer, M.D.; Magnuson, M.A.; Fazio, S.; Linton, M.F. Conditional knockout of macrophage PPARgamma increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol., 2005, 25, 1647-1653.
35. Ricote, M.; Li, A.C.; Willson, T.M.; Kelly, C.J.; Glass, C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature, 1998, 391, 79-82.
36. de Dios, S.T.; Hannan, K.M.; Dilley, R.J.; Hill, M.A.; Little, P.J. Troglitazone, but not rosiglitazone, inhibits Na/H exchange activity and proliferation of macrovascular endothelial cells. J. Diabetes Complications, 2001, 15, 120-127.
37. Gouni-Berthold, I.; Sachinidis, A. Inhibition of the Low Density Lipoprotein-Induced Vascular Smooth Muscle Cell Growth by PPARgamma Ligands. Drug News Perspect, 2002, 15, 5-9.
38. Ogawa, D.; Nomiyama, T.; Nakamachi, T.; Heywood, E.B.; Stone, J.F.; Berger, J.P.; Law, R.E.; Bruemmer, D. Activation of peroxisome proliferator-activated receptor gamma suppresses telomerase activity in vascular smooth muscle cells. Circ. Res., 2006, 98, e50-e59.
39. Marx, N.; Froehlich, J.; Siam, L.; Ittner, J.; Wierse, G.; Schmidt, A.; Scharnagl, H.; Hombach, V.; Koenig, W. Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol., 2003, 23, 283-288.
40. Sugawara, A.; Takeuchi, K.; Uruno, A.; Ikeda, Y.; Arima, S.; Sato, K.; Kudo, M.; Taniyama, Y.; Ito, S. Differential effects among thiazolidinediones on the transcription of thromboxane receptor and angiotensin II type 1 receptor genes. Hypertens. Res., 2001, 24, 229-233.
41. Sugawara, A.; Takeuchi, K.; Uruno, A.; Ikeda, Y.; Arima, S.; Kudo, M.; Sato, K.; Taniyama, Y.; Ito, S. Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-gamma in vascular smooth muscle cells. Endocrinology, 2001, 142, 3125-3134.
42. Okura, T.; Nakamura, M.; Takata, Y.; Watanabe, S.; Kitami, Y.; Hiwada, K. Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells. Eur. J. Pharmacol., 2000, 407, 227-235.
43. Lin, Y.; Zhu, X.; McLntee, F.L.; Xiao, H.; Zhang, J.; Fu, M.; Chen, Y.E. Interferon regulatory factor-1 mediates PPARgamma-induced apoptosis in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol., 2004, 24, 257-263.
44. Redondo, S.; Ruiz, E.; Santos-Gallego, C.G.; Padilla, E.; Tejerina, T. Pioglitazone induces vascular smooth muscle cell apoptosis through a peroxisome proliferator-activated receptor-gamma, transforming growth factor-beta1, and a Smad2-dependent mechanism. Diabetes, 2005, 54, 811-817.
45. Shoelson, S.E.; Lee, J.; Goldfine, A.B. Inflammation and insulin resistance. J. Clin. Invest., 2006, 116, 1793-1801.
46. Tontonoz, P.; Nagy, L.; Alvarez, J.G.; Thomazy, V.A.; Evans, R.M. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell, 1998, 93, 241-252.
47. Nagy, L.; Tontonoz, P.; Alvarez, J.G.; Chen, H.; Evans, R.M. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell, 1998, 93, 229-240.
48. Huang, J.T.; Welch, J.S.; Ricote, M.; Binder, C.J.; Willson, T.M.; Kelly, C.; Witztum, J.L.; Funk, C.D.; Conrad, D.; Glass, C.K. Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature, 1999, 400, 378-382.
49. Li, A.C.; Brown, K.K.; Silvestre, M.J.; Willson, T.M.; Palinski, W.; Glass, C.K. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. Clin. Invest., 2000, 106, 523-531.
50. Chawla, A.; Barak, Y.; Nagy, L.; Liao, D.; Tontonoz, P.; Evans, R.M. PAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat. Med., 2001, 7, 48-52.
51. Chen, Z.; Ishibashi, S.; Perrey, S.; Osuga, J.; Gotoda, T.; Kitamine, T.; Tamura, Y.; Okazaki, H.; Yahagi, N.; Iizuka, Y.; Shionoiri, F.; Ohashi, K.; Harada, K.; Shimano, H.; Nagai, R.; Yamada, N. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Arterioscler. Thromb. Vasc. Biol., 2001, 21, 372-377.
52. Collins, A.R.; Meehan, W.P.; Kintscher, U.; Jackson, S.; Wakino, S.; Noh, G.; Palinski, W.; Hsueh, W.A.; Law, R.E. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol., 2001, 21, 365-371.
53. Chawla, A.; Boisvert, W.A.; Lee, C.H.; Laffitte, B.A.; Barak, Y.; Joseph, S.B.; Liao, D.; Nagy, L.; Edwards, P.A.; Curtiss, L.K.; Evans, R.M.; Tontonoz, P. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol. Cell, 2001, 7, 161-171.
54. Chinetti, G.; Lestavel, S.; Bocher, V.; Remaley, A.T.; Neve, B.; Torra, I.P.; Teissier, E.; Minnich, A.; Jaye, M.; Duverger, N.; Brewer, H.B.; Fruchart, J.C.; Clavey, V.; Staels, B. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat. Med., 2001, 7, 53-58.
55. Akiyama, T.E.; Sakai, S.; Lambert, G.; Nicol, C.J.; Matsusue, K.; Pimprale, S.; Lee, Y.H.; Ricote, M.; Glass, C.K.; Brewer, H.B.; Jr.; Gonzalez, F.J. Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol. Cell Biol., 2002, 22, 2607-2619.
56. Li, A.C.; Binder, C.J.; Gutierrez, A.; Brown, K.K.; Plotkin, C.R.; Pattison, J.W.; Valledor, A.F.; Davis, R.A.; Willson, T.M.; Witztum, J.L.; Palinski, W.; Glass, C.K. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/ delta, and gamma. J. Clin. Invest., 2004, 114, 1564-1576.
57. Jiang, C.; Ting, A.T.; Seed, B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature, 1998, 391, 82-86.
58. Welch, J.S.; Ricote, M.; Akiyama, T.E.; Gonzalez, F.J.; Glass, C.K. PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. Proc. Natl. Acad. Sci. USA, 2003, 100, 6712-6717.
59. Kintscher, U.; Goetze, S.; Wakino, S.; Kim, S.; Nagpal, S.; Chandraratna, R.A.; Graf, K.; Fleck, E.; Hsueh, W.A.; Law, R.E. Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes. Eur. J. Pharmacol., 2000, 401, 259-270.
60. Han, K.H.; Chang, M.K.; Boullier, A.; Green, S.R.; Li, A.; Glass, C.K.; Quehenberger, O. Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator-activated receptor gamma. Clin. Invest., 2000, 106, 793-802.
61. Yano, M.; Matsumura, T.; Senokuchi, T.; Ishii, N.; Motoshima, H.; Taguchi, T.; Matsuo, T.; Sonoda, K.; Kukidome, D.; Sakai, M.; Kawada, T.; Nishikawa, T.; Araki, E. Troglitazone inhibits oxidized low-density lipoprotein-induced macrophage proliferation: Impact of the suppression of nuclear translocation of ERK1/2. Atherosclerosis, 2007, 191(1), 22-32.
62. Chinetti, G.; Griglio, S.; Antonucci, M.; Torra, I.P.; Delerive, P.; Majd, Z.; Fruchart, J.C.; Chapman, J.; Najib, J.; Staels, B. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J. Biol. Chem., 1998, 273, 25573-25580.
63. Pascual, G.; Fong, A.L.; Ogawa, S.; Gamliel, A.; Li, A.C.; Perissi, V.; Rose, D.W.; Willson, T.M.; Rosenfeld, M.G.; Glass, C.K. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature, 2005, 437, 759-763.
64. Lehrke, M.; Lazar, M.A. The many faces of PPARgamma. Cell, 2005, 123, 993-999.
65. Haffner, S.M.; Lehto, S.; Ronnemaa, T.; Pyorala, K.; Laakso, M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J Med., 1998, 339, 229-234.
66. Haffner, S.M.; Greenberg, A.S.; Weston, W.M.; Chen, H.; Williams, K.; Freed, M.I. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation, 2002, 106, 679-684.
67. Kim, S.G.; Ryu, O.H.; Kim, H.Y.; Lee, K.W.; Seo, J.A.; Kim, N.H.; Choi, K.M.; Lee, J.; Baik, S.H.; Choi, D.S. Effect of rosiglitazone on plasma adiponectin levels and arterial stiffness in subjects with prediabetes or non-diabetic metabolic syndrome. Eur. J. Endocrinol., 2006, 154, 433-440.
68. Zimmet, P. Addressing the insulin resistance syndrome: a role for the thiazolidinediones. Trends Cardiovasc. Med., 2002, 12, 354-362.
69. Campia, U.; Matuskey, L.A.; Panza, J.A. Peroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors. Circulation, 2006, 113, 867-875.
70. Itoh, H.; Doi, K.; Tanaka, T.; Fukunaga, Y.; Hosoda, K.; Inoue, G.; Nishimura, H.; Yoshimasa, Y.; Yamori, Y.; Nakao, K. Hypertension and insulin resistance: role of peroxisome proliferator-activated receptor gamma. Clin. Exp. Pharmacol Physiol., 1999, 26, 558-560.
71. Martin-Nizard, F.; Furman, C.; Delerive, P.; Kandoussi, A.; Fruchart, J.C.; Staels, B.; Duriez, P. Peroxisome proliferator-activated receptor activators inhibit oxidized low-density lipoprotein-induced endothelin-1 secretion in endothelial cells. J. Cardiovasc. Pharmacol., 2002, 40, 822-831.
72. Esposito, K.; Ciotola, M.; Carleo, D.; Schisano, B.; Saccomanno, F.; Sasso, F.C.; Cozzolino, D.; Assaloni, R.; Merante, D.; Ceriello, A.; Giugliano, D. Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. Diabetes Care, 2006, 29, 1071-1076.
73. Cho, D.H.; Choi, Y.J.; Jo, S.A.; Jo, I. Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone: evidence for involvement of peroxisome proliferator-activated receptor (PPAR) gamma-dependent and PPARgamma-independent signaling pathways. J. Biol. Chem., 2004, 279, 2499-2506.
74. Sidhu, J.S.; Cowan, D.; Kaski, J.C. Effects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus. Am. J. Cardiol., 2004, 94, 151-156.
75. Sidhu, J.S.; Cowan, D.; Kaski, J.C. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J. Am. Coll. Cardiol., 2003, 42, 1757-1763.
76. Charbonnel, B.; Dormandy, J.; Erdmann, E.; Massi-Benedetti, M.; Skene, A. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care, 2004, 27, 1647-1653.
77. Dormandy, J.A.; Charbonnel, B.; Eckland, D.J.; Erdmann, E.; Massi-Benedetti, M.; Moules, I.K.; Skene, A.M.; Tan, M.H.; Lefebvre, P.J.; Murray, G.D.; Standl, E.; Wilcox, R.G.; Wilhelmsen, L.; Betteridge, J.; Birkeland, K.; Golay, A.; Heine, R.J.; Koranyi, L.; Laakso, M.; Mokan, M.; Norkus, A.; Pirags, V.; Podar, T.; Scheen, A.; Scherbaum, W.; Schernthaner, G.; Schmitz, O.; Skrha, J.; Smith, U.; Taton, J. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet, 2005, 366, 1279-1289.
78. Rizza, R.; Henry, R.; Kahn, R. Commentary on the results and clinical implications of the PROactive study. Diabetes Care, 2005, 28, 2965-2967.
79. Minamikawa, J.; Tanaka, S.; Yamauchi, M.; Inoue, D.; Koshiyama, H. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J. Clin. Endocrinol. Metab., 1998, 83, 1818-1820.
80. Koshiyama, H.; Shimono, D.; Kuwamura, N.; Minamikawa, J.; Nakamura, Y. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J. Clin. Endocrinol. Metab., 2001, 86, 3452-3456.
81. Marx, N.; Wohrle, J.; Nusser, T.; Walcher, D.; Rinker, A.; Hombach, V.; Koenig, W.; Hoher, M. Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation, 2005, 112, 2792-2798.
82. Meisner, F.; Walcher, D.; Gizard, F.; Kapfer, X.; Huber, R.; Noak, A.; Sunder-Plassmann, L.; Bach, H.; Haug, C.; Bachem, M.; Stojakovic, T.; Marz, W.; Hombach, V.; Koenig, W.; Staels, B.; Marx, N. Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients: data from a randomized placebo-controlled trial. Arterioscler. Thromb. Vasc. Biol., 2006, 26, 845-850.
83. Chen, S.; Noguchi, Y.; Izumida, T.; Tatebe, J.; Katayama, S. A comparison of the hypotensive and hypoglycaemic actions of an angiotensin converting enzyme inhibitor, an AT1a antagonist and troglitazone. J. Hypertens., 1996, 14, 1325-1330.
84. Saku, K.; Zhang, B.; Ohta, T.; Arakawa, K. Troglitazone lowers blood pressure and enhances insulin sensitivity in Watanabe heritable hyperlipidemic rabbits. Am. J. Hypertens., 1997, 10, 1027-1033.
85. Wu, L.; Wang, R.; De Champlain, J.; Wilson, T.W. Beneficial and deleterious effects of rosiglitazone on hypertension development in spontaneously hypertensive rats. Am. J. Hypertens., 2004, 17, 749-756.
86. Ogihara, T.; Rakugi, H.; Ikegami, H.; Mikami, H.; Masuo, K. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am. J.Hypertens., 1995, 8, 316-320.
87. Nolan, J.J.; Ludvik, B.; Beerdsen, P.; Joyce, M.; Olefsky, J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N. Engl. J. Med., 1994, 331, 1188-1193.
88. Honisett, S.Y.; Stojanovska, L.; Sudhir, K.; Kingwell, B.A.; Dawood, T.; Komesaroff, P.A. Rosiglitazone lowers blood pressure and increases arterial compliance in postmenopausal women with type 2 diabetes. Diabetes Care, 2003, 26, 3194-3195.
89. Sarafidis, P.A.; Lasaridis, A.N.; Nilsson, P.M.; Pagkalos, E.M.; Hitoglou-Makedou, A.D.; Pliakos, C.I.; Kazakos, K.A.; Yovos, J.G.; Zebekakis, P.E.; Tziolas, I.M.; Tourkantonis, A.N. Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase. J. Hypertens., 2004, 22, 1769-1777.
90. Gaillard, V.; Casellas, D.; Seguin-Devaux, C.; Schohn, H.; Dauca, M.; Atkinson, J.; Lartaud, I. Pioglitazone improves aortic wall elasticity in a rat model of elastocalcinotic arteriosclerosis. Hypertension, 2005, 46, 372-379.
91. Ryan, M.J.; Didion, S.P.; Mathur, S.; Faraci, F.M.; Sigmund, C.D. PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension, 2004, 43, 661-666.
92. Gao, D.F.; Niu, X.L.; Hao, G.H.; Peng, N.; Wei, J.; Ning, N.; Wang, N.P. Rosiglitazone inhibits angiotensin II-induced CTGF expression in vascular smooth muscle cells - Role of PPAR-gamma in vascular fibrosis. Biochem. Pharmacol., 2007, 73, 185-197.
93. Kurtz, T.W. Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator. Acta. Diabetol., 2005, 42(Suppl. 1), S9-16.
94. Schupp, M.; Clemenz, M.; Gineste, R.; Witt, H.; Janke, J.; Helleboid, S.; Hennuyer, N.; Ruiz, P.; Unger, T.; Staels, B.; Kintscher, U. Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes, 2005, 54, 3442-3452.
95. Benson, S.C.; Pershadsingh, H.A.; Ho, C.I.; Chittiboyina, A.; Desai, P.; Pravenec, M.; Qi, N.; Wang, J.; Avery, M.A.; Kurtz, T.W. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension, 2004, 43, 993-1002.
96. Gerstein, H.C.; Yusuf, S.; Bosch, J.; Pogue, J.; Sheridan, P.; Dinccag, N.; Hanefeld, M.; Hoogwerf, B.; Laakso, M.; Mohan, V.; Shaw, J.; Zinman, B.; Holman, R.R. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet, 2006, 368, 1096-1105.
97. Nesto, R.W.; Bell, D.; Bonow, R.O.; Fonseca, V.; Grundy, S.M.; Horton, E.S.; Le Winter, M.; Porte, D.; Semenkovich, C.F.; Smith, S.; Young, L.H.; Kahn, R. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care, 2004, 27, 256-263.
98. Nesto, R.W.; Bell, D.; Bonow, R.O.; Fonseca, V.; Grundy, S.M.; Horton, E.S.; Le Winter, M.; Porte, D.; Semenkovich, C.F.; Smith, S.; Young, L.H.; Kahn, R. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation, 2003, 108, 2941-2948.
99. Najman, D.M. Adverse events related to muraglitazar use in diabetes. JAMA, 2006, 295, 1997.
100. Kendall, D.M.; Rubin, C.J.; Mohideen, P.; Ledeine, J.M.; Belder, R.; Gross, J.; Norwood, P.; O'Mahony, M.; Sall, K.; Sloan, G.; Roberts, A.; Fiedorek, F.T.; DeFronzo, R.A. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study. Diabetes Care, 2006, 29, 1016-1023.
101. Harrity, T.; Farrelly, D.; Tieman, A.; Chu, C.; Kunselman, L.; Gu, L.; Ponticiello, R.; Cap, M.; Qu, F.; Shao, C.; Wang, W.; Zhang, H.; Fenderson, W.; Chen, S.; Devasthale, P.; Jeon, Y.; Seethala, R.; Yang, W.P.; Ren, J.; Zhou, M.; Ryono, D.; Biller, S.; Mookhtiar, K.A.; Wetterau, J.; Gregg, R.; Cheng, P.T.; Hariharan, N. Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice. Diabetes, 2006, 55, 240-248.
102. He, Y.; Jiang, B.; Wang, J.; Feng, K.; Chang, Q.; Fan, L.; Li, X.; Hu, F.B. Prevalence of the metabolic syndrome and its relation to cardiovascular disease in an elderly Chinese population. J. Am. Coll. Cardiol., 2006, 47, 1588-1594.
103. Alberti, K.G.; Zimmet, P.; Shaw, J. The metabolic syndrome - a new worldwide definition. Lancet, 2005, 366, 1059-1062.
104. Cheung, B.M. The metabolic syndrome in China. Br. J. Clin. Pharmacol., 2006, 62, 260-263.
105. Gu, D.; Reynolds, K.; Wu, X.; Chen, J.; Duan, X.; Reynolds, R.F.; Whelton, P.K.; He, J. Prevalence of the metabolic syndrome and overweight among adults in China. Lancet, 2005, 365, 1398-1405.